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Fingerprint changes in CSF composition
associated with different aetiologies in human
neonatal hydrocephalus: glial proteins associated
with cell damage and loss
Irum Naureen1,6, Khawaja A Irfan Waheed2, Ahsen W Rathore2, Suresh Victor3, Conor Mallucci4, John R Goodden5,
Shahid N Chohan6 and Jaleel A Miyan1*
Abstract
Background: In hydrocephalus an imbalance between production and absorption of cerebrospinal fluid (CSF) results
in fluid accumulation, compression and stretching of the brain parenchyma. In addition, changes in CSF composition
have a profound influence on the development and function of the brain and together, these can result in severe
life-long neurological deficits. Brain damage or degenerative conditions can result in release of proteins expressed
predominantly in neurons, astroglia, or oligodendroglia into the brain interstitial fluid, CSF and blood. Determination
of such products in the CSF might be of value in diagnosing cause, aetiology and/or assessing the severity of the
neurological damage in patients with hydrocephalus. We therefore analysed CSF from human neonates with
hydrocephalus for these proteins to provide an insight into the pathophysiology associated with different aetiologies.
Methods: CSF was collected during routine lumbar puncture or ventricular tap. Samples were categorized according
to age of onset of hydrocephalus and presumed cause (fetal-onset, late-onset, post-haemorrhagic or spina bifida with
hydrocephalus). Glial fibrillary acidic protein (GFAP), myelin basic protein (MBP), vimentin and 2′ , 3′-cyclic nucleotide
3′-phosphodiesterase (CNPase) were analysed through Western blotting of hydrocephalic CSF samples (n = 17) and
compared with data from CSF of normal infants without neurological deficits (n = 8).
Results: GFAP was significantly raised only in CSF from post-haemorrhagic hydrocephalus while MBP was significantly
raised in post-haemorrhagic and in spina bifida with hydrocephalus infants. Vimentin protein was only detected in
some CSF samples from infants with late-onset hydrocephalus but not from other conditions. Surprisingly, CNPase was
found in all neonatal CSF samples, including normal and hydrocephalic groups, although it was reduced in infants with
late onset hydrocephalus compared with normal and other hydrocephalic groups.
(Continued on next page)
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Conclusions: Apart from CNPase, which is an enzyme, the markers investigated are intracellular intermediate
filaments and would be present in CSF only if the cells are compromised and the proteins released. Raised GFAP
observed in post-haemorrhagic hydrocephalus must reflect damage to astrocytes and ependyma. Raised MBP in
post-haemorrhagic and spina bifida with hydrocephalus indicates damage to oligodendrocytes and myelin.
Vimentin protein detected in some of the late-onset hydrocephalic samples indicates damage to glial and other
progenitors and suggests this condition affects periventricular regions. The presence of CNPase in all CSF samples
was unexpected and indicates a possible novel role for this enzyme in brain development/myelination. Less CNPase in
some cases of late-onset hydrocephalus could therefore indicate changes in myelination in these infants. This study
demonstrates differential glial damage and loss in the developing human neonatal hydrocephalic brain associated with
different aetiologies.
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Background
Hydrocephalus is a pathological condition characterised
by an abnormal production and/or absorption of cere-
brospinal fluid (CSF). The aetiology of hydrocephalus is
unclear, even with some evidence of genetic predispos-
ition [1]. With a global incidence of 1:500 (NIH, USA),
hydrocephalus affects between 1:100–1:5000 live human
births with a lower incidence in developed countries
achieved through elective terminations. Hydrocephalus
can result in deficient/abnormal cerebral cortex develop-
ment and lifelong neurological deficits [2-4]. The patho-
physiology of hydrocephalus in neonates remains poorly
understood since they do not experience raised intracra-
nial pressure despite accumulation of CSF in the brain
accompanied by ventricular and cranial expansion [5,6].
The extent of ventricular dilation depends on the loca-
tion of CSF blockage and length of time of the block
[7,8]. Fetal-onset ventriculomegally (enlarged ventricles
without raised pressure) is thought to result in more se-
vere brain damage [3,4] but recent studies challenge this
notion [9] even though ventricular expansion, and con-
sequential compression and stretching of the brain must
have a damaging effect in severe cases. Currently the
only control measure is birth termination and the only
treatment option is surgical fluid diversion. Although
surgery does address the life-threatening raised intracra-
nial pressure, compression and stretching of the brain
parenchyma, it does not recover lost or abnormal devel-
opment, cellular damage or the life-long neurological is-
sues resulting from these [4-6].
Improvements in prenatal diagnosis and treatment will
raise the quality of life for children with hydrocephalus
through decreased mortality and morbidity, but this may
only be through a better understanding of the underlying
aetiology and biological basis of the condition and the
development of additional treatments to shunt surgery.
The literature in both human and experimental animal
studies is not clear with controversy on cause and with
much work targeted at understanding the consequences
of raised pressure rather than possible earlier events, due
in large part to the view of CSF as a mechanical support
fluid rather than a fluid with physiological importance.
The latter role of CSF is currently under considerable re-
view and renewed research [10-13] with some new in-
sights emerging into the unique part played by CSF in
development and brain function [9,14,15]. Recent research
has focused on the interplay between CSF signals and
their role in normal neurodevelopment [11-13], and there
is growing evidence that secreted proteins or other factors
within the CSF have an age-dependent effect on neural
cell precursor proliferation and cortical development [14].
Thus, major alterations in CSF protein composition in
neonatal neurological disease states could have direct and
significant effects on global neurodevelopment [16]. Alter-
natively an imbalance in the levels of specific CSF proteins
may directly affect on-going neurodevelopmental pro-
cesses, which could lead to the developmental defects as-
sociated with post-haemorrhagic hydrocephalus [17] as
well as those already associated with CSF composition
changes in fetal-onset hydrocephalus [9,18,19].
The severity of hydrocephalus is usually assessed from
clinical signs and symptoms. In very young patients an
increase in head circumference usually occurs with only
minor symptoms due to the compliance of the immature
skull. CT-scanning and intracranial pressure-monitoring
have proved to be valuable tools in the assessment of the
diagnosis, but many patients still do not show satisfac-
tory outcomes after CSF shunt surgery [20] suggesting an
underlying pathophysiological process may not have been
addressed by the procedure. The outcome, in terms of
possible neurological deficits, may reflect these under-
lying processes that are not addressed by shunting and
thus do not reflect the brain damage that is directly
inflicted by hydrocephalus [4,20,21]. These deficits may
not be rescued or recovered [22] and may be a conse-
quence of poor, or abnormal development of the cerebral
cortex [18,19]. Thus, although appropriate diagnostics
have been developed for hydrocephalus, the potential of
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biological markers to characterise the underlying patho-
logical processes has so far been overlooked.
The composition of the CSF should reflect physio-
logical/biochemical changes happening in the brain par-
enchyma, and more particularly in the periventricular
white matter and sub-ventricular zones lining the ventri-
cles [23,24] where atrophy of the white matter, and to
some extent the grey matter and damage to axons were
found in various hydrocephalic conditions [3,4,25-28]. In
the neonatal period a major phase of gliogenesis occurs
in the ventricular and sub-ventricular zones and it is
likely that there is a significant effect from hydroceph-
alus on developing glial cells, but less effect on the post-
mitotic neurones produced prenatally [29-32]. The aim
of this study was to test whether different aetiologies of
neonatal hydrocephalus were correlated with different
profiles of proteins associated with glial damage in hu-
man neonatal hydrocephalus.
Materials and methods
Patient samples
Prior to the study, ethical approval was obtained from
the UK NHS REC (ref: 08/H1015/43), Central Manchester
NHS Foundation Trust, Alder Hey Children’s Hospital,
Leeds Teaching Hospitals NHS Trust, The University of
Manchester, and The Children’s Hospital Lahore. Written
informed consent for participation and demographic data
including sex, age and ethnicity were obtained from each
patient’s parents using their home language with verbal
explanation where necessary. This study is based on 25
neonates, 16 males and 9 females varying in age from 1 to
44 weeks (Table 1). CSF samples were collected by trained
clinical staff either by lumbar puncture from normal in-
fants (n = 8), presenting with mild fever and suspected
meningitis but sera negative, or through insertion of
catheters into the brain lateral ventricle to drain fluid
from infants with hydrocephalus. All CSF samples were
sera negative for known infective organisms. Any sera
positive samples were excluded from this study as were
all samples with obvious blood contamination. The
procedures and tests were part of the routine clinical
management of the patients and we obtained fluid excess
to clinical test requirements. Samples were frozen at -80°C
within 30 min of collection. UK samples were transported
frozen on dry ice while samples collected from Lahore
Children’s Hospital, Pakistan, were lyophilised (freeze
dried) prior to shipment for analysis in the UK. Lyophi-
lised samples were reconstituted to the original volume
using deionised water (Milli-Q) before analysis. For obvi-
ous clinical reasons it was not possible to obtain CSF sam-
ples from the same site in normal and hydrocephalus
infants. Total protein would be higher in lumber CSF but
other parameters would be expected to be within normal
ranges unless damage, inflammation or infection affected
specific regions. Any significant differences between hydro-
cephalus groups were directly comparable to each other as
they were all ventricular samples, but any differences to
normal lumbar CSF samples needed to be interpreted with
due regard to reported differences between lumbar and
ventricular CSF. Obstruction of CSF outflow may also
affect composition but one aim of the current study is to
determine if CSF composition is indeed altered, by what-
ever mechanism, in hydrocephalus.
We received limited information concerning each
sample so that sub-categorisation based on severity of
hydrocephalus, neurological deficits etc. was not possible
in this initial study. Thus, we categorised hydrocephalic
CSF samples according to age of onset and the cause of
hydrocephalus into the following groups: 1. Fetal-onset
or congenital hydrocephalus (FOH) in infants born with
classically enlarged heads and associated neurological
symptoms (n = 4); 2. Late-onset hydrocephalus (LOH) in
infants developing hydrocephalus some days or weeks
after birth due to undetermined factors but probably
infections (n = 4); 3. Post-haemorrhagic hydrocephalus
(PHH) in infants due to an intraventricular or subarach-
noid bleed before, during or soon after birth (n = 5); 4.
Spina bifida with hydrocephalus (SB/HC) in infants with
a primary neural tube defect (n = 4). 5. Control/normal
infants with no neurological condition and sera negative
for meningitis (n = 8). Sample details are summarised in
Table 1.
Table 1 Clinical variables of the normal and hydrocephalic neonates used in the study
Patient groups Age (days) Sex ratio
(male: female)
Site of CSF
collection
Source
(UK: Pakistan)Groups n Age range (days after birth) Mean SEM
Normal 8 8-92 24.50 9.72 5:3 Lumber 0:8
FOH 4 11-30 18.25 4.40 4:0 Lateral ventricle 1:3
LOH 4 60-300 153.75 55.58 3:1 Lateral ventricle 0:4
PHH 5 28-132 74.80 22.05 2:3 Lateral ventricle 5:0
SB/HC 4 5-105 41.00 22.79 2:2 Lateral ventricle 4:0
Number of patients, age (days post-partum), gender, and national distribution of the patients studied grouped by known aetiology. Late onset hydrocephalus
(LOH) and spina bifida with hydrocephalus (SB/HC) infants are somewhat older than the other groups due to the nature of the condition and the time to receiving
treatment. All CSF samples were collected from the lateral ventricle except normal samples that were collected by lumbar puncture. Although there is an age
range in each group the low number of samples did not allow analysis of age-related changes. FOH: fetal-onset hydrocephalus, PHH: post-haemorrhagic hydrocephalus.
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Western blotting
All CSF samples were compared through analysis of equal
volumes. This was the most meaningful approach since
we expected to see changes in total protein as well as in
individual components. The specifications for each anti-
body on the manufacturer’s web sites also listed previous
publications characterising the antibody as well as its spe-
cificity and utility for identifying the target protein. All
samples were diluted 1:1 by volume in Laemmli sample
buffer (BioRad 161–0737, Hemel Hempstead, UK) con-
taining mercaptoethanol and heated for 7 min at 95°C.
Protein standards were included in each gel as well as a
molecular weight standard (Biorad161-0375). Rat (post-
natal day 1) astrocyte cell lysates (5–10 μg, see below)
were used as a positive control for GFAP and vimentin
antibodies. The CNPase antibody was well characterised
by previous studies of oligodendrocytes and cortical white
matter [33,34]. Furthermore, we had previous data from
mass spectrometry that CNPase was indeed present in
CSF samples [35]. 5 μl of each CSF sample were separated
together with control proteins and molecular weight
markers on a 4-12% SDS-PAGE gel and transferred to
a PVDF membrane using an iBlot system with blotting
kits (Invitrogen, Glasgow, UK). The membranes were
blocked using 5% skimmed-milk (Marvel) or 5% fish
skin gelatine (Sigma Poole, UK) in 0.1% phosphate-
buffer solution (pH 7.4) with 0.1% Tween (Sigma) for
1 hour at room temperature (RT). Primary antibodies
were optimised to the following dilutions for 1:4000
(0.25 μg/ml) for rabbit anti-human GFAP (Abcam
7779, Cambridge, UK ), 1:1000 (0.1 μg/ml) for rabbit
anti-human Vimentin (Cell Signaling-3932, New Eng-
land Biolabs, Hitchin, UK), 1:10,000 (0.1 μg/ml) for
rabbit anti-human MBP (Thermo Fisher PA1-18324
Lutterworth, UK), 1:1000 (0.1 μg/ml) for rabbit anti-
human CNPase (Sigma C9743) were diluted in blocking
solution and membranes incubated overnight at 4°C with-
out agitation. Membranes were then washed and incubated
in a 1:3000 dilution of the secondary antibody, horseradish
peroxidise-conjugated anti-rabbit IgG (Cell signalling
7074) in blocking solution for 1h at RT with agitation,
washed and the signals detected using an enhanced
chemiluminescence substrate (Amersham Hyper film
ECL, GE Healthcare Little Chalfont, UK) and exposed
to film.
Astrocyte cell lysates
In order to produce astrocyte cell lysates for positive
control, 1-day old Sprague–Dawley rat pups (Charles
River, Ormiston, Scotland) were killed with an overdose
of sodium pentobarbitone given by intraperitoneal injec-
tion and then decapitated. 2–4 cerebral hemispheres
were dissected under sterile conditions in a laminar flow
hood. The cortical hemispheres were placed in ice-cold
Dulbecco’s modified medium (DMEM, Invitrogen, Glasgow,
UK) and further dissected under a stereo microscope
(Leica M3Z). The meninges were removed and the cho-
roid plexus removed from the ventricle. All cleaned
hemispheres were then digested with trypsin and gently
dissociated through decreasing bore sizes of sterile pi-
pettes. The suspension was centrifuged for 10 min at
1000 rpm, the supernatant discarded and the pellet re-
suspended in DMEM. After a further centrifugation and
resuspension to wash the cells, the pellet was resuspended
in 10 ml of DMEM per hemisphere. 10 ml of cell suspen-
sion was loaded into poly-D-lysine coated 75 cm2 flasks
and placed in a humidified incubator for 7–9 days at 37°C
with 5% CO2. After 7–9 day incubation, flasks were sealed
tight and shaken on an orbital shaker at 230 rpm for
4 hours at 37°C to separate microglial cells from astro-
cytes. The media was replaced with 10 ml of fresh DMEM
and shaken for a further 1 h. The culture was then washed
twice with 5 ml of warm PBS with gentle mixing and then
the adherent astrocytes lysed using CelLytic M Cell Lysis
Reagent (Sigma) for 15 min at room temperature. Cells
were scraped off the flask and the whole media centri-
fuged to remove cell debris. Protein concentration was
measured using a Bradford Assay and 5-10 μg total protein
loaded on gels as a control for GFAP and vimentin.
Densitometry and statistical analysis
Films were scanned and the relative density of bands
quantified using Image J (Version 1.44p, NIH). Where
no bands were obvious a measure of the staining (pre-
sumably background) where the band would have been
was used for those CSF samples. Data are presented as
mean ± SEM. Results of the experiments were entered
into Graphpad Prism V software and the data analysed
using one way analysis of variance (ANOVA) and post
hoc (Tukey) testing to identify significant differences
between groups. The value p < 0.05 was considered sig-
nificant. No distribution tests were carried out and the
data was assumed to fall within a normal distribution.
Results
Glial fibrillary acidic protein (GFAP)
A 53KDa, GFAP-positive protein band present in the CSF
from PHH and SB/HC infants was not detected in normal,
FOH and LOH samples (Figure 1a). This GFAP-positive
protein was significantly increased in PHH (P < 0.05) and
showed a non-significant increase in SB/HC CSF when
compared with CSF from normal infants (Figure 1b).
Vimentin
A 55KDa vimentin-positive protein band was observed in
the CSF from two infants with LOH but was barely de-
tected in normal, FOH, PHH or SB/HC infants (Figure 2a).
The presence or absence of the vimentin positive band in
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different LOH infants gave a non-significant (P > 0.05)
statistical test (Figure 2b) against normal. Two of four
LOH samples have obviously raised levels of vimentin
compared to any other individual tested.
Myelin basic protein (MBP)
A 40 KDa MBP-positive protein band was observed in
the CSF from infants with PHH and SB/HC conditions
but was below the detection limit in CSF from normal,
FOH and LOH infants (Figure 3a). MBP showed a highly
significant (P > 0.0001) increase in CSF of PHH and SB/
HC infants compared to normal. The elevation of MBP
in PHH and SB/HC infants showed little variation be-
tween different samples analysed.
2′ , 3′-cyclic nucleotide 3′-phosphodiesterase (CNPase)
A 45 KDa CNPase-positive protein band was detected
in all samples of CSF analysed (Figure 4a). CNPase was
significantly lower in LOH (P < 0.05) although one in-
fant had normal levels. CNPase was reduced but with-
out significance in FOH compared with CSF from
normal, PHH and SB/HC infants (Figure 4b).
(a)
SB/HC
(b)
*
Figure 1 Western blot analyses for glial fibrillary acidic protein (GFAP). a. Western blots for GFAP. Ten-lane precast gels were used. Each
lane had an individual 5 μl sample of CSF from the categories of patients shown. After protein separation using SDS PAGE they were blotted onto a
PVDF membrane for probing with antibodies. ECL detection was used to visualise the labelled bands and for semi-quantitative analysis using Image-J
software. A single 53 KDa band was labelled using the antibody to GFAP and only found in PHH and SB/HC samples as shown in this representative
gel. All samples were run on at least 3 gels with a total number in each group as noted for the semi-quantitative analysis. FOH: fetal-onset
hydrocephalus, LOH: late-onset hydrocephalus, PHH: post-haemorrhagic hydrocephalus, SB/HC: spina bifida with hydrocephalus. b. Semi-quantitative
analysis of the 53 KDa band labelled with anti-GFAP antibody. Values are Mean ± SEM of Normal n = 8, FOH n = 4, LOH n = 4, PHH n = 5, SB/HC n = 4.
Only PHH showed a significant difference from normal which had undetectable levels so that the difference was effectively from zero protein (P < 0.05
indicated by asterisk *). SB/HC also shows an increase but this was not significantly different from normal. Rat (postnatal P1) astrocytes cell lysates were
used as a positive control for the GFAP antibody and these are shown in the last lane.
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Discussion
The present study determined CSF levels of GFAP, vimen-
tin, MBP and CNPase in human neonatal hydrocephalus
with different aetiologies compared to CSF from neonates
with no neurological abnormalities. Although significant
differences as well as non-significant indications of differ-
ences have been found, the low number of samples avail-
able for analysis limited clear conclusions. The study does
show that differences are likely to exist and that a larger
study is urgently needed. There are clearly sub-categories
within each group that show significant changes and so
further clinical data may unravel these issues. The proteins
we analysed are intermediate filaments found in astrocytes,
ependymal cells (GFAP) early glial progenitors and dif-
ferentiating astrocytes (vimentin) and oligodendrocytes
(MBP) and an enzyme associated with the formation of
myelin in oligodendrocytes (CNPase). Their presence
in CSF is thus thought to indicate cell compromise,
(b)
(a)
SB/HC
Figure 2 Western blot analyses for vimentin. a. Western blots for vimentin. Ten-lane precast gels were used. Each lane had an individual
5 μl sample of CSF from the categories of patients shown. After protein separation using SDS PAGE they were blotted onto a PVDF membrane
for probing with antibodies. ECL detection was used to visualise the labelled bands and for semi-quantitative analysis using Image-J software. A
single 55 KDa band was labelled using the antibody to vimentin and only detected in 2 of the 4 LOH samples or glial cell lysates (last lane except
for LOH where it was not run on this particular gel) as shown in these representative gels. All samples were run a minimum of 3 times with a
total number of samples as given for semi-quantitative analysis. No significant differences to normal were detected in any group even LOH where
two samples had this protein and 2 not. A greater sample number is needed to test if vimentin is generally present in LOH or not. Patient groups
as for Figure 1. b. Semi-quantitative analysis of the 55 KDa band labelled with anti-vimentin antibody relative to the background stain of normal
samples where this protein was not detected. Values are Mean ± SEM of Normal n = 8, FOH n = 4, LOH n = 4, PHH n = 4, SB/ HC n = 4. Rat (postnatal
P1) astrocyte cell lysates were used as a positive control for the vimentin antibody. No significant differences were found.
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breakdown and release of intracellular components. In this
study we found that FOH, the congenital form of hydro-
cephalus, is not associated with any appearance of cell
breakdown products in agreement with previous studies
demonstrating absence of cell death [36] and decreased cell
proliferation with a cell cycle arrest in the H-Tx rat model
of FOH [18,19]. LOH had only vimentin detectable in CSF
while PHH and SB/HC had GFAP and MBP but not
vimentin in CSF. Interestingly, CNPase has never been de-
scribed in normal/developmental CSF but we found it in
all samples of CSF including those from our non-
hydrocephalic control infants. We found it reduced in 3 of
4 samples of LOH compared to other samples and it is in-
teresting to speculate whether the 4th sample might have
had a non-infectious cause compared to the normal cause
in this category of hydrocephalus. Its presence in all neo-
natal CSF samples analysed suggests a possible role in the
immediate post-natal acceleration of gliogenesis. The
source of CSF CNPase must surely be oligodendrocytes
and their precursors since no other cell has been shown
to express this enzyme. This potential role as a secreted
molecule remains to be investigated. It would be very
(a)
SB/HC
(b)
******
Figure 3 Western blot analyses for myelin basic protein (MBP). a. Western blots for MBP. Ten-lane precast gels were used. Each lane had
an individual 5 μl sample of CSF from the categories of patients shown. After protein separation using SDS PAGE they were blotted onto a PVDF
membrane for probing with antibodies. ECL detection was used to visualise the labelled bands and for semi-quantitative analysis using Image-J
software. A single 40 KDa band was labelled using the antibody to myelin basic protein and only detected in PHH and SB/HC samples as shown in this
representative gel. All samples were run a minimum of three times with a total number of samples as given for semi-quantitative analysis. Patient
groups as for Figure 1. b. Semi-quantitative analysis of the 40 KDa band labelled with anti-MBP antibody. MBP was increased significantly (P < 0.001)
in PHH and SB/HC compared to undetectable levels in normal, FOH and LOH infants. Values are Mean ± SEM of Normal n = 4, FOH n = 4, LOH n = 4,
PHH n = 4, SB/HC n = 4. Values in PHH are SB/HC are significantly different to the undetectable level in normal, so effectively from the zero protein
level, P < 0.001 indicated by asterisks ***.
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interesting to test CNPase on the differentiation of oligo-
dendrocytes from cortical stem/progenitor cells in in vitro
cell culture as well as to investigate the factors stimulating
secretion of this enzyme from oligodendrocytes.
GFAP is an intermediate filament expressed in mature
astrocytes [37,38] and immature ependymal cells [39].
Thus the GFAP seen in hydrocephalic CSF may originate
from either source as the ependyma is likely to be matur-
ing in the neonatal period. Our findings support those re-
ported for experimental neonatal acquired hydrocephalus
[3,4] and also show that congenital and late-onset
hydrocephalus, the latter associated with neonatal and
postnatal infections, do not present with raised GFAP but
that PHH and SB/HC neonates do. GFAP was reported in
the CSF of elderly normal pressure hydrocephalus (NPH)
patients compared with neurologically healthy age-
matched controls [40,41] suggesting a common patho-
physiology involving astroglial damage in these types of
hydrocephalus, but astroglial protection in FOH and LOH
in the neonate. This protection may not be present in
older untreated individuals. The latter point is supported
by findings in hydrocephalic H-Tx rats in which reactive
(a)
*
(b)
Figure 4 Western blot analyses for 2′ , 3′-cyclic nucleotide 3′-phosphodiesterase (CNPase). a. Western blots for CNPase. Ten-lane precast
gels were used. Each lane had an individual 5 μl sample of CSF from the categories of patients shown. After protein separation using SDS PAGE they
were blotted onto a PVDF membrane for probing with antibodies. ECL detection was used to visualise the labelled bands and for semi-quantitative
analysis using Image-J software. A single 45 KDa band was labelled using the antibody to CNPase and was detected in all samples as shown in these
representative gels. All samples were run a minimum of three times with a total number of samples as shown for semi-quantitative analysis. Patient
groups as for Figure 1. b. Semi-quantitative analysis of the 45 KDa band labelled with anti-CNPase antibody shows similar levels of CNPase to that in
normal CSF in FOH, PHH and SB/HC but in the LOH group where a significant reduction (P < 0.05 indicated by asterisk *) was observed compared to
normal and other hydrocephalic groups. In the LOH gel 3 of the 4 samples show reduced CNPase compared to normal and one sample not. Increased
numbers will provide better resolution of this particular group. Values are Mean ± SEM of Normal n = 4, FOH n = 4, LOH n = 4, PHH n = 4, SB/HC n = 4.
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astrogliosis and microgliosis were observed and corre-
lated with the severity of hydrocephalus and increasing
age [42]. Moreover, Del Bigio et al. reported signifi-
cantly increased GFAP levels in hydrocephalic rats
which decreased after shunting suggesting an effect of
fluid accumulation and/or raised intracranial pressure
on these cells [43]. Similar increased GFAP RNA and
protein levels were observed in 10-day old kaolin-
induced hydrocephalic kittens which also decreased
after shunting [44]. Ependymal damage is well docu-
mented in hydrocephalus as is astrogliosis so it is per-
haps not surprising to find GFAP in CSF as a
consequence of specific insults. The finding that GFAP
is not present in CSF from FOH and LOH must there-
fore indicate protection of these cells from damage in
these forms of hydrocephalus. Thus, the current study
indicates early-stage pathology differs depending on
etiology.
MBP in CSF is an indicator of damage specifically asso-
ciated with myelination as this protein is only known to
be present in oligodendrocytes [45,46]. MBP is an import-
ant marker to study in hydrocephalus since the degree of
pathology and functional neurological deficits are largely
associated with lack of, or damage to myelination, e.g. of
the corpus callosum and periventricular white matter. We
found significantly elevated levels of MBP in the CSF of
infants with PHH and SB/HC indicating that demyelin-
ation, and/or a failure of myelination is likely to be occur-
ring in these conditions, but not in FOH or LOH. The
intraventricular or subarachnoid bleeding in PHH is likely
to contribute directly to brain damage [47] and to the de-
myelination of the periventricular white matter reported
in PHH. Sutton et al., [48] reported the presence of MBP
protein in the CSF of hydrocephalic patients with different
aetiologies and suggested that active hydrocephalus, asso-
ciated with progressive ventricular dilatation, would pro-
duce periventricular demyelination through mechanical
stretching of the brain parenchyma. Increased intracranial
pressure has a greater impact on early cognitive develop-
ment than increased CSF volume, and the negative effect
is partially reversible through early ventricular shunting
[49] giving improved myelination. The fact that MBP is
not detected in FOH and LOH again indicates a lack of
direct pathology in these specific aetiologies of hydroceph-
alus and the possibility to prevent loss of myelination
through early intervention.
Vimentin is a cytoskeletal intermediate filament in-
volved in maintaining cell integrity in many different
cells types including fibroblasts and endothelial cells [50]
as well as progenitor cells and early neuronal and glial
cells [51-53]. Vimentin is found in neuronal stem and
progenitor cells and astrocytes during the early postnatal
period and re-expressed in reactive astrocytes in cases of
central nervous system injury [54-56]. Microglial cells
also express vimentin, specifically after brain damage and/
or activation through local inflammatory mediators [57]. In
hydrocephalus vimentin-positive cells increase around dis-
rupted areas of ependyma suggesting that reactive microglia
and proliferating immature glial cells are associated with
areas of ependymal cell loss [58]. Our data would further
suggest that these cells may be compromised by fluid accu-
mulation and raised intracranial pressure. The increased
levels of vimentin in the LOH infants must be a direct con-
sequence of infection affecting the brain but the lack of
GFAP in LOH indicates that the source is unlikely to be
astroglial and may be microglial, endothelial or leptomenin-
geal since many patients present with meningitis. This
requires further analysis as it indicates a very different
pathophysiology in these patients compared to those
with other aetiologies of hydrocephalus.
CNPase is a protein accounting for approximately 4%
of myelin protein content and is considered an index of
myelin formation [59,60] where the amount of immuno-
reactive CNPase correlates with the thickness of the
myelin sheath in the central nervous system [61,62]. Wu
and colleagues [63] reported that they also found CNPase
expressed in prenatal and early postnatal microglial cells
in rat brain with a gradual decrease with age, essentially
undetectable after birth. They suggested that downregula-
tion of CNPase related to the transformation of microglia
from the mobile and amoeboid type to the ramified type
during development. If confirmed the finding of CNPase
in non-myelin producing cells presents a further mystery
regarding its functions along with its presence in CSF
found in the current study. Absence of CNPase results in
serious conditions. CNPase-knockout mice show severe
symptoms, including convulsions and ataxia, and most
homozygous mice die between 6 and 12 months of age
[64]. Decrease in CNPase expression is also observed in
chronic schizophrenic patients [65] indicating a possible
involvement in the underlying developmental pathology.
In kaolin-induced hydrocephalic rats Del Bigio et al.
[43] reported decreased CNPase in the corpus callo-
sum/supraventricular white matter, fimbria, medulla,
and spinal cord indicating a sensitivity of myelin in
these regions to raised intracranial pressure. Furthermore,
a reduction in the number of CNPase immunoreactive oli-
godendrocytes both in the subependymal layer and the
cerebral cortex of hydrocephalic rat brains correlated with
the severity of the hydrocephalus [66]. CNPase has not
been described in neonatal CSF before this study and was
an unexpected finding particularly its presence in all
neonatal CSF samples tested. LOH had reduced CNPase
in CSF compared to normal and other conditions. As
CNPase is thought to be involved in oligodendrocyte
surface membrane expansion and migration during early
stages of axonal ensheathment [67], its presence in CSF
may indicate a potential role in global brain myelination
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not previously considered. This requires further study but
may prove to be an important tool in promoting myelin-
ation in affected brains.
This study has a number of limitations. Firstly, to ob-
tain CSF free of contamination excluded many collected
samples so that a much larger study is required to investi-
gate our current findings in more detail. Secondly, it is
practically impossible to obtain CSF samples through
ventricular catheterisation from healthy neonates due to
technical limitations and ethical issues. Similarly, it is
unusual to obtain lumbar CSF from hydrocephalic pa-
tients. Although some reports indicate that ventricular
CSF may be more stable and accurate for measuring
pathological changes [68], others contradict this [69].
For our study, all normal samples were taken by lumbar
puncture while all hydrocephalic CSF came from lateral
ventricles. We assumed that only obstructive hydro-
cephalus would produce a change in ventricular CSF
that was not reflected in lumbar drainage but also ac-
knowledge reported differences in total protein between
lumbar and ventricular CSF which we believe would not
affect the validity of our findings since we are looking
for changes in specific proteins associated with path-
ology. Of note here is the finding of CNPase in both
normal and affected neonatal CSF at equal levels (except
in LOH) that supports an argument that the measure-
ments are comparable in this study.
Taken together, the findings of this study indicate that
different aetiologies leading to hydrocephalus are associ-
ated with different pathophysiological mechanisms af-
fecting different cell types, at least in the initial stages
where intracranial pressure may not be pathologically
raised. The congenital form of hydrocephalus has no de-
tectable pathological markers in CSF but is known to be
affected by a physiological block of cell cycle as well as a
folate block [18,19]. Differential diagnosis is therefore
possible and the potential for more effective treatment of
these different conditions may emerge from further re-
search. Further studies are clearly needed and, with more
detailed clinical data, e.g., measurements of ventriculomeg-
ally and additional radiographical data on brain measures,
developmental and neurological signs and symptoms,
as well as pre- and post-surgical data, a more robust
differential diagnostic is likely to emerge which would
feed into research for differential treatment depending
on the characterisation of the underlying pathology.
Furthermore, we have focused on glial cell effects but
additional data on neuronal status is also needed in dif-
ferentiating between the different aetiologies leading to
hydrocephalus.
Conclusions
This study has demonstrates that different aetiologies
leading to neonatal hydrocephalus can likely be
differentiated by CSF analysis. This presents an import-
ant step in understanding this devastating neurological
condition. These results suggest that early-stage changes
are associated, not with raised pressure, but with
currently unknown physiological changes that affect dif-
ferent cell types in different locations within the hydro-
cephalic brain. Shunting will only address the common
end point of these different aetiologies and is unlikely to
address the underlying differences in physiology. It is
therefore important to understand these physiological
processes in order to prevent irreversible cell damage
and lasting neurological deficits.
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